Search

Your search keyword '"Nebot, N"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Nebot, N" Remove constraint Author: "Nebot, N"
21 results on '"Nebot, N"'

Search Results

1. Arquitectura y salud. Aprendiendo de la enfermedad

3. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

4. French Intensive Care Society, International congress - Réanimation 2016

5. CNS tumours The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas

6. Sorafenib Hepatobiliary Disposition: Mechanisms of Hepatic Uptake and Disposition of Generated Metabolites

8. 613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors

9. Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)

10. French Intensive Care Society, International congress – Réanimation 2016

11. Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).

12. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors.

13. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

14. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.

15. Systematic prevention of severe constipation induced by antipsychotic agents: A quasi-experimental study.

16. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.

17. Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.

18. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.

19. Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.

20. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.

21. Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.

Catalog

Books, media, physical & digital resources